PUBLIC COMPANY
saveElectra Therapeutics Inc
updated 2mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
- phase1A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
- phase1Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Volunteers
🐶 Hiring Signal
News
- ADARx raises $446M in biotech’s third largest IPO of 2026, City files to go publicTwo RNA biotechs, ADARx Pharmaceuticals and City Therapeutics, are taking advantage of the IPO frenzy, which has led to a total of 27 newly public biotechs so far this year.biospace · 5d ago
- Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitzNovo plans to hit $23B in revenue by 2035, has further reduced its workforce by 4,000 and is boosting manufacturing capacity for its Wegovy pill, but investors are unconvinced it will be enough to…biospace · 7d ago
- Electra lights up with $350M IPO for pivotal immune-disease drug developmentElectra Therapeutics has exceeded its initial fundraising plans as it becomes the 26th biotech to debut publicly this year and outlines pivotal development plans for its monoclonal antibody ipsopru…biospace · 12d ago
- This week in charts: GSK’s China deals, the $300M IPO club and selling the newsThe latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall Street analysts and a closer look at an industry-leading partnership streak.biopharma_dive · 12d ago
- Inflammation biotech Electra charges up with $350M from upsized IPOElectra Therapeutics is the latest biotech to overshoot its own IPO expectations this year, with the inflammation-focused company bringing in $350 million from this morning’s Nasdaq listing.fiercebiotech · 12d ago
- Electra's $350M IPO will help it become a commercial biotechElectra Therapeutics became the 21st biotech of 2026 to go through with an IPO after pricing its $350 million Nasdaq debut on Thursday evening. The Bay Area biotech will use the ...endpoints · 12d ago
- Electra amasses $350M in biotech’s latest big IPONearly a dozen biotechnology firms have matched or raised more than $300 million in their initial public offerings in 2026, a figure not seen since new stock sales peaked in 2021, according to BioP…biopharma_dive · 12d ago
- Electra aims for nearly $300M IPO; Enhertu's Phase 3 lung cancer successPlus news about Lilly, Cellectis, Tyra, Shennon and QL Biopharm. Electra Therapeutics eyes $297M IPO: The Sanofi-backed biotech hopes to kick off the post-Labor Day IPO train with a nearly $300 mil…endpoints · 16d ago
- Electra aims for $342M IPO to power inflammatory drug’s push through phase 3Electra Therapeutics is hoping to raise up to $341.9 million from an IPO in order to power the clinical development of its inflammatory disorder drug, ipsoprubart.fiercebiotech · 16d ago
- Sanofi-backed Electra files for IPO to fund Phase 2/3 immunology drugBiotech's IPO summer isn't over yet. Electra Therapeutics plans to begin public trading on the Nasdaq after the Labor Day holiday, according to a Friday IPO filing with securities regulators. While…endpoints · 1mo ago
comments(0)
5-min edit window · permanent after that